MX2016006583A - Tratamiento de hipercolesterolemia familiar homocigotica. - Google Patents
Tratamiento de hipercolesterolemia familiar homocigotica.Info
- Publication number
- MX2016006583A MX2016006583A MX2016006583A MX2016006583A MX2016006583A MX 2016006583 A MX2016006583 A MX 2016006583A MX 2016006583 A MX2016006583 A MX 2016006583A MX 2016006583 A MX2016006583 A MX 2016006583A MX 2016006583 A MX2016006583 A MX 2016006583A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- homocigotic
- inhibitor
- family hypercholesterolemia
- hypercholesterolemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361906837P | 2013-11-20 | 2013-11-20 | |
| US201461942438P | 2014-02-20 | 2014-02-20 | |
| US201461942941P | 2014-02-21 | 2014-02-21 | |
| US201461974816P | 2014-04-03 | 2014-04-03 | |
| US201461974725P | 2014-04-03 | 2014-04-03 | |
| US201461974785P | 2014-04-03 | 2014-04-03 | |
| PCT/US2014/065742 WO2015077154A1 (en) | 2013-11-20 | 2014-11-14 | Treatment of homozygous familial hypercholesterolemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016006583A true MX2016006583A (es) | 2016-09-06 |
Family
ID=52014370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006583A MX2016006583A (es) | 2013-11-20 | 2014-11-14 | Tratamiento de hipercolesterolemia familiar homocigotica. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150139987A1 (enExample) |
| EP (1) | EP3071198A1 (enExample) |
| JP (1) | JP2017505285A (enExample) |
| KR (1) | KR20160079124A (enExample) |
| CN (1) | CN105764498A (enExample) |
| AU (1) | AU2014353246A1 (enExample) |
| CA (1) | CA2930069A1 (enExample) |
| CL (1) | CL2016001215A1 (enExample) |
| EA (1) | EA201691039A1 (enExample) |
| HK (1) | HK1224186A1 (enExample) |
| IL (1) | IL245748A0 (enExample) |
| MX (1) | MX2016006583A (enExample) |
| PH (1) | PH12016500886A1 (enExample) |
| WO (1) | WO2015077154A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| HUE035887T2 (en) | 2012-12-05 | 2018-05-28 | Alnylam Pharmaceuticals Inc | PCSK9 iRNA preparations and methods for their use |
| WO2015121877A2 (en) * | 2014-02-17 | 2015-08-20 | Hetero Research Foundation | Polymorphs of lomitapide and its salts |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| SI3119384T1 (sl) | 2014-03-20 | 2018-12-31 | Cymabay Therapeutics, Inc. | Zdravljenje intrahepatičnih holestatičnih bolezni |
| HRP20192299T1 (hr) | 2014-04-11 | 2020-03-06 | Cymabay Therapeutics, Inc. | Liječenje nafld i nash |
| BR102015025502B1 (pt) * | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
| CN108348541A (zh) * | 2015-08-25 | 2018-07-31 | 阿尔尼拉姆医药品有限公司 | 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物 |
| CN105481758A (zh) * | 2016-01-13 | 2016-04-13 | 天津药物研究院有限公司 | 一种洛美他派晶型ⅰ及其制备方法和用途 |
| MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| MA44764B1 (fr) * | 2016-04-28 | 2025-09-30 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de patients présentant une hypercholestérolémie familiale |
| WO2017200715A1 (en) * | 2016-05-19 | 2017-11-23 | Cymabay Therapeutics, Inc. | Treatment of severe hyperlipidemia |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| CN111836620B (zh) * | 2017-11-23 | 2023-11-03 | 浙江海正药业股份有限公司 | 一种海泽麦布和HMG-CoA还原酶抑制剂的药物组合物 |
| CA3123844A1 (en) * | 2018-12-20 | 2020-06-25 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating familial hypercholesterolemia |
| DK3911648T3 (da) | 2019-01-18 | 2025-01-13 | Astrazeneca Ab | 6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf |
| WO2021097027A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of alcoholic liver disease |
| US20210145775A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of intestinal barrier dysfunction and associated diseases |
| AU2021316011A1 (en) | 2020-07-29 | 2023-02-09 | Amryt Pharmaceuticals Inc. | Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| ATE542793T1 (de) | 2003-09-19 | 2012-02-15 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga |
| JP5697296B2 (ja) | 2004-03-05 | 2015-04-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法 |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| JP5694941B2 (ja) | 2008-10-17 | 2015-04-01 | シーマベイ セラピューティクス，インコーポレイティド | 小型高密度ｌｄｌ粒子を減少させる方法 |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
-
2014
- 2014-11-14 CN CN201480063803.XA patent/CN105764498A/zh active Pending
- 2014-11-14 US US14/541,835 patent/US20150139987A1/en not_active Abandoned
- 2014-11-14 JP JP2016532631A patent/JP2017505285A/ja not_active Withdrawn
- 2014-11-14 WO PCT/US2014/065742 patent/WO2015077154A1/en not_active Ceased
- 2014-11-14 CA CA2930069A patent/CA2930069A1/en not_active Abandoned
- 2014-11-14 HK HK16112450.0A patent/HK1224186A1/zh unknown
- 2014-11-14 KR KR1020167016225A patent/KR20160079124A/ko not_active Withdrawn
- 2014-11-14 EA EA201691039A patent/EA201691039A1/ru unknown
- 2014-11-14 AU AU2014353246A patent/AU2014353246A1/en not_active Abandoned
- 2014-11-14 EP EP14809184.6A patent/EP3071198A1/en not_active Withdrawn
- 2014-11-14 MX MX2016006583A patent/MX2016006583A/es unknown
-
2016
- 2016-05-12 PH PH12016500886A patent/PH12016500886A1/en unknown
- 2016-05-19 IL IL245748A patent/IL245748A0/en unknown
- 2016-05-20 CL CL2016001215A patent/CL2016001215A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105764498A (zh) | 2016-07-13 |
| CL2016001215A1 (es) | 2016-12-09 |
| EP3071198A1 (en) | 2016-09-28 |
| KR20160079124A (ko) | 2016-07-05 |
| US20150139987A1 (en) | 2015-05-21 |
| AU2014353246A1 (en) | 2016-06-16 |
| WO2015077154A1 (en) | 2015-05-28 |
| EA201691039A1 (ru) | 2016-11-30 |
| IL245748A0 (en) | 2016-07-31 |
| HK1224186A1 (zh) | 2017-08-18 |
| CA2930069A1 (en) | 2015-05-28 |
| JP2017505285A (ja) | 2017-02-16 |
| PH12016500886A1 (en) | 2016-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016006583A (es) | Tratamiento de hipercolesterolemia familiar homocigotica. | |
| CL2017000705A1 (es) | Nuevos compuestos | |
| IL282535A (en) | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors | |
| CR20150418A (es) | Compuestos de tetrahidropirrolotiazina | |
| UY36315A (es) | COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6. | |
| JO3392B1 (ar) | مركبات عطرية حلقية غير متجانسة كمركبات مضادة للالتهاب | |
| BR112015000160A2 (pt) | fabricação de ácido 2-(5-bromo-4-(4-ciclopropil hidronaftalen-1-il)-4h-1,2,4-triazol-3-il-tio) acético | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| AR098274A1 (es) | Inhibidor de grelina o-acil transferasa | |
| CY1122264T1 (el) | Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων | |
| DK2987791T3 (da) | 3-(4-(Benzyloxy)phenyl)hex-4-insyre-derivat, egnet til forebyggelse og behandling af metaboliske sygdomme | |
| CL2015002309A1 (es) | Proceso de fabricacion de vortioxetina. | |
| CL2016003290A1 (es) | Tratamiento de hipertrigliceridemia severa. | |
| EA201690911A1 (ru) | Соединения диметилбензойной кислоты | |
| CL2018000057A1 (es) | Composiciones farmacéuticas que comprenden un antagonista de la integrina alfa4 para uso en el tratamiento de afecciones inflamatorias oculares | |
| EA201390616A1 (ru) | ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2 | |
| EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
| MX376785B (es) | Surtidor operado por bateria. | |
| EA201790191A1 (ru) | Новые сульфониламинобензамидные соединения | |
| EP3314851A4 (en) | SINGLE SOLUTION FOR USER CONTROL | |
| PE20171259A1 (es) | Compuestos | |
| EA201690593A1 (ru) | Новые соединения мочевины | |
| DOP2017000016A (es) | Nueva sal de disoproxilo de tenofovir | |
| AR119050A2 (es) | Compuestos del ácido 3,6-diclorosalicílico y procesos de síntesis relacionados | |
| BR112013025399A2 (pt) | máquina para o vazamento de barris de forma automática e higiênica |